<DOC>
	<DOC>NCT01398592</DOC>
	<brief_summary>This study is designed to assess the potential difference in Fasting Plasma Glucose (FPG) lowering efficacy between the two DPP-4 inhibitors vildagliptin and sitagliptin, both after a two weeks treatment on top of metformin.</brief_summary>
	<brief_title>Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients with type 2 diabetes 18 to 85 years Metformin monotherapy &gt; 4 weeks HbA1c 6.5 9.5% FPG &gt; 270 mg/dl Use of other antidiabetic drugs than metformin major cardiovascular event in the last 6 months (MI, strokeâ€¦)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Diabetes mellitus Type two</keyword>
	<keyword>T2DM</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>FPG</keyword>
	<keyword>DPP-4</keyword>
</DOC>